Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and aBRCAmutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

(2015) G. Kim et al.   CLINICAL CANCER RESEARCH

Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development

(2015) Clare L. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation

(2014) Linus Jönsson et al.   VALUE IN HEALTH

Adjusting overall survival for treatment switches: commonly used methods and practical application

(2013) Claire Watkins et al.   PHARMACEUTICAL STATISTICS

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

(2012) L. C. Hanker et al.   ANNALS OF ONCOLOGY

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007

(2008) C Sue Richards et al.   GENETICS IN MEDICINE

Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials

(2008) Christopher K. Daugherty et al.   JOURNAL OF CLINICAL ONCOLOGY